Literature DB >> 2015730

Salivary analysis for determination of dextromethorphan metabolic phenotype.

Z Y Hou1, L W Pickle, P S Meyer, R L Woosley.   

Abstract

Debrisoquin oxidative phenotype is a determinant of pharmacologic response for many drugs. Poor and extensive metabolizers can be identified by the dextromethorphan metabolic ratio (dextromethorphan/dextrorphan). We developed and tested a method to determine debrisoquin phenotype on the basis of the metabolic ratio in saliva. Each of 62 normal volunteers was given a 50 mg capsule of dextromethorphan hydrobromide and collected urine (0 to 8 hours) and saliva (at 3 hours). Dextromethorphan and dextrorphan in saliva and urine were assayed by HPLC. The distributions of paired urinary and 3-hour salivary metabolic ratios of samples from 61 subjects were compared. The urinary and salivary metabolic ratios were distributed trimodally and bimodally, respectively. The Spearman rank correlation coefficient for logarithm of urinary metabolic ratio vs that of salivary metabolic ratio was 0.704. All the poor metabolizers identified by urinary metabolic ratio were also identified by the metabolic ratio in saliva at 3 hours (100% concordance). This study demonstrates that salivary analysis for determination of dextromethorphan metabolic phenotype is feasible.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2015730     DOI: 10.1038/clpt.1991.48

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

1.  Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.

Authors:  S Hägg; O Spigset; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

Review 2.  Alternative Sampling Strategies for Cytochrome P450 Phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

Review 3.  Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.

Authors:  Timothy S Tracy; Amarjit S Chaudhry; Bhagwat Prasad; Kenneth E Thummel; Erin G Schuetz; Xiao-Bo Zhong; Yun-Chen Tien; Hyunyoung Jeong; Xian Pan; Laura M Shireman; Jessica Tay-Sontheimer; Yvonne S Lin
Journal:  Drug Metab Dispos       Date:  2015-12-17       Impact factor: 3.922

Review 4.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

5.  Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan.

Authors:  N E Basci; A Bozkurt; S O Kayaalp; A Sayal; A Isimer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

Review 6.  Drug monitoring in nonconventional biological fluids and matrices.

Authors:  S Pichini; I Altieri; P Zuccaro; R Pacifici
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

7.  Farnesoid X Receptor Agonist Represses Cytochrome P450 2D6 Expression by Upregulating Small Heterodimer Partner.

Authors:  Xian Pan; Yoon-Kwang Lee; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2015-04-29       Impact factor: 3.922

Review 8.  Clinical significance of genetic influences on cardiovascular drug metabolism.

Authors:  L Arcavi; N L Benowitz
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

9.  Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.

Authors:  Silvana Borges; Zeruesenay Desta; Yan Jin; Azzouz Faouzi; Jason D Robarge; Sanosh Philips; Santosh Philip; Anne Nguyen; Vered Stearns; Daniel Hayes; James M Rae; Todd C Skaar; David A Flockhart; Lang Li
Journal:  J Clin Pharmacol       Date:  2010-01-15       Impact factor: 3.126

10.  Debrisoquine hydroxylation in a Polish population.

Authors:  P K Kunicki; D Sitkiewicz; A Pawlik; V Bielicka-Sulzyc; E Borowiecka; B Gawrońska-Szklarz; R Sterna; H Matsumoto; M Radziwoń-Zaleska
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.